Business of Optometry News

The FDA granted regenerative medicine advanced therapy designation to ATSN-201, a gene therapy candidate for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

Things will be a little different ahead of this year’s American Society of Cataract and Refractive Surgery meeting in Los Angeles as ASCRS debuts SightLine, a new single-day meeting.

  Tenpoint Therapeutics submitted a new drug application to the FDA for Brimochol PF, an eye drop for presbyopia treatment, according to a press release.

With tax season here, physicians juggling hectic clinical schedules must also focus on optimizing their financial strategies. With proper planning, physicians can take advantage of key tax-saving opportunities to maximize their wealth.

  The FDA issued a complete response letter for the resubmission of the reproxalap new drug application for the treatment of signs and symptoms of dry eye disease, according to a press release from Aldeyra Therapeutics.

Alcon introduced the Clareon PanOptix Pro trifocal IOL, which will be commercially available in the U.S. in May, for patients with cataracts, according to a press release.

Reaching a comfortable retirement is the number one financial goal for nearly all physicians.

Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.

ORLANDO — Lumenis announced the launch of OptiLift, a dynamic muscle stimulation technology intended to improve lower eyelid laxity, blink quality and eyelid function, at Vision Expo East.